Application of Comprehensive Non-invasive Assessment To Phenotype Tricuspid Regurgitation

Launched by PRINCE OF WALES HOSPITAL, SHATIN, HONG KONG · Jun 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a heart condition called tricuspid regurgitation (TR), where a heart valve doesn’t close properly, causing blood to flow backward. TR is common in people with certain types of heart failure and can lead to serious health problems. The study aims to better understand TR by using non-invasive tests—meaning no surgery or needles—to look at how the heart, liver, and lungs are working together in these patients. These tests include measuring liver stiffness and lung fluid levels with special devices. The goal is to use this information to predict health outcomes and help doctors create more personalized treatment plans for people with TR.

Adults aged 65 and older who have at least moderate TR and can give consent may be eligible to join. However, people with certain other heart valve problems, very weak heart function, previous tricuspid valve procedures, or specific liver and lung conditions are not eligible. Participants can expect regular check-ups using non-invasive tests that measure heart function, liver health, and lung fluid. These tests are painless and done without surgery. By taking part, patients may help improve future care for people with TR, especially as new treatment options are becoming available.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with \>=moderate TR
• • able to consent for the study.
• Exclusion Criteria:
• • 1. LVEF \<=40%
• • 2. Have significant left sided organic valvular heart disease (i.e. \>=moderate AS, \>=moderate MS, \>=moderate MR of organic or mixed aetiology), dysfunctional mitral valve replacement or aortic valve replacement
• • 3. Prior tricuspid valve interventions (eg TriClip, tricuspid valve repair or replacement) (To allow accurate transient elastography)
• • 4. Known hepatocellular carcinoma
• • 5. Known portal vein thrombosis
• • 6. Established liver cirrhosis with a known liver-related aetiology
• • 7. Hepatitis C infection and not on treatment
• • 8. Uncontrolled hepatitis (e.g. hepatitis B infection, autoimmune hepatitis)
• • 9. Fatty liver with evidence of non-alcoholic fatty liver disease or cirrhosis (to allow accurate non-invasive lung fluid assessment)
• • 10. recent rib fracture (\<3 months) with or without flail chest
• • 11. BMI \<20 or \>36
• • 12. Height \<155cm or \>195cm
• • 13. Patients with right lung tumor
• • 14. Patients with right sided pacemaker
• • 15. Patients with known underlying exudative right pleural effusion